Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Depreciation and Depletion (2023 - 2024)

Seres Therapeutics' Depreciation and Depletion history spans 2 years, with the latest figure at $333000.0 for Q3 2024.

  • For Q3 2024, Depreciation and Depletion changed N/A year-over-year to $333000.0; the TTM value through Dec 2024 reached $989000.0, changed N/A, while the annual FY2024 figure was $989000.0, 51.02% down from the prior year.
  • Depreciation and Depletion for Q3 2024 was $333000.0 at Seres Therapeutics, up from $328000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $551000.0 in Q4 2023 and bottomed at $328000.0 in Q1 2024.